JP2015513919A - 膵癌細胞への治療的送達および診断的送達のためのｒｎａアプタマー - Google Patents

膵癌細胞への治療的送達および診断的送達のためのｒｎａアプタマー Download PDF

Info

Publication number
JP2015513919A
JP2015513919A JP2015505732A JP2015505732A JP2015513919A JP 2015513919 A JP2015513919 A JP 2015513919A JP 2015505732 A JP2015505732 A JP 2015505732A JP 2015505732 A JP2015505732 A JP 2015505732A JP 2015513919 A JP2015513919 A JP 2015513919A
Authority
JP
Japan
Prior art keywords
pancreatic cancer
seq
aptamer
cell
pancreatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015505732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513919A5 (enExample
Inventor
ロッシ，ジョン，ジェイ
ヨーン，ソラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015513919A publication Critical patent/JP2015513919A/ja
Publication of JP2015513919A5 publication Critical patent/JP2015513919A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015505732A 2012-04-10 2013-03-13 膵癌細胞への治療的送達および診断的送達のためのｒｎａアプタマー Pending JP2015513919A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261622375P 2012-04-10 2012-04-10
US61/622,375 2012-04-10
PCT/US2013/031074 WO2013154735A1 (en) 2012-04-10 2013-03-13 Rna aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells

Publications (2)

Publication Number Publication Date
JP2015513919A true JP2015513919A (ja) 2015-05-18
JP2015513919A5 JP2015513919A5 (enExample) 2016-04-28

Family

ID=49328023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015505732A Pending JP2015513919A (ja) 2012-04-10 2013-03-13 膵癌細胞への治療的送達および診断的送達のためのｒｎａアプタマー

Country Status (6)

Country Link
US (2) US9464293B2 (enExample)
EP (1) EP2836501B1 (enExample)
JP (1) JP2015513919A (enExample)
AU (1) AU2013246419A1 (enExample)
CA (1) CA2870288A1 (enExample)
WO (1) WO2013154735A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017073535A1 (ja) * 2015-10-30 2017-05-04 タグシクス・バイオ株式会社 癌細胞に結合するｄｎａアプタマー

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019025681B1 (pt) 2012-11-01 2023-04-18 Factor Bioscience Inc Método para inserir uma sequência de ácido nucleico em uma localização segura de um genoma de uma célula
WO2014144744A1 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Aptamer methods and compositions
MX373332B (es) * 2013-07-26 2020-05-21 Univ Iowa Res Found UNA PARTÍCULA rAAV Y UN AGENTE DE INMUNOSUPRESIÓN PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES.
WO2015184224A1 (en) * 2014-05-30 2015-12-03 Academia Sinica Aptamer targeting mage-a3 peptide and uses thereof
CN107106697B (zh) * 2014-10-15 2021-06-18 希望之城 Pdgfr rna适体
US10550394B2 (en) 2015-03-31 2020-02-04 City Of Hope Anti-cancer RNA aptamers
US11219635B2 (en) 2016-02-19 2022-01-11 City Of Hope Bi-specific aptamer
WO2017173247A1 (en) * 2016-03-31 2017-10-05 City Of Hope Aptamer compositions and the use thereof
WO2019033050A1 (en) * 2017-08-11 2019-02-14 City Of Hope BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN
EP3664814A4 (en) 2017-08-11 2021-05-05 City of Hope Rna aptamers against transferrin receptor (tfr)
ES2925031T3 (es) * 2017-12-21 2022-10-13 Marelli Automotive Lighting Italy Spa Faro de vehículo con partes a diferentes niveles de luminancia
US11225665B2 (en) 2019-06-20 2022-01-18 City Of Hope P38 map kinase inhibitors
KR102294694B1 (ko) * 2019-07-18 2021-08-30 국립암센터 신규한 dna 앱타머 및 이의 용도
JP2024515220A (ja) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
EP4551705A2 (en) 2022-07-06 2025-05-14 Molecular Axiom, Llc Compositions and methods for treating pancreatic cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010140834A2 (ko) * 2009-06-01 2010-12-09 성균관대학교산학협력단 췌장암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073207A1 (en) * 1997-01-31 2003-04-17 Saghir Akhtar Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
WO1999065928A2 (en) 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
US20030064946A1 (en) * 2000-08-09 2003-04-03 Mcswiggen James Method and reagent for the inhibition of calcium activated chloride channel-1 (CLCA-1)
CN100419426C (zh) 2002-04-22 2008-09-17 佛罗里达州立大学 功能化纳米微粒及其使用方法
EP2977470B1 (en) * 2002-10-16 2018-01-03 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7655785B1 (en) * 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US20100254901A1 (en) * 2005-07-28 2010-10-07 Smith Cassandra L Compositions comprising nucleic acid aptamers
GB2437727B (en) 2006-05-04 2011-04-20 Univ Open Aptamers directed to MUC1
WO2007128109A1 (en) * 2006-05-04 2007-11-15 University Health Network Aptamers that recognize the carbohydrate n-acetylgalactosamine (galnac)
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US20090169613A1 (en) * 2007-11-09 2009-07-02 Reznik Boris N Targeting of tumor stem cells through selective silencing of boris expression
WO2009129465A2 (en) * 2008-04-17 2009-10-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of xbp-1 gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010140834A2 (ko) * 2009-06-01 2010-12-09 성균관대학교산학협력단 췌장암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017073535A1 (ja) * 2015-10-30 2017-05-04 タグシクス・バイオ株式会社 癌細胞に結合するｄｎａアプタマー
JPWO2017073535A1 (ja) * 2015-10-30 2018-08-16 タグシクス・バイオ株式会社 癌細胞に結合するｄｎａアプタマー
JP7041517B2 (ja) 2015-10-30 2022-03-24 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌細胞に結合するｄｎａアプタマー
JP2022061987A (ja) * 2015-10-30 2022-04-19 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌細胞に結合するｄｎａアプタマー
JP7391074B2 (ja) 2015-10-30 2023-12-04 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌細胞に結合するｄｎａアプタマー

Also Published As

Publication number Publication date
EP2836501A4 (en) 2016-03-09
CA2870288A1 (en) 2013-10-17
US20160201059A1 (en) 2016-07-14
AU2013246419A1 (en) 2014-10-30
US9464293B2 (en) 2016-10-11
WO2013154735A1 (en) 2013-10-17
US20150197752A1 (en) 2015-07-16
EP2836501B1 (en) 2018-03-07
EP2836501A1 (en) 2015-02-18

Similar Documents

Publication Publication Date Title
US9464293B2 (en) RNA aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells
Gong et al. A smart multiantenna gene theranostic system based on the programmed assembly of hypoxia-related siRNAs
Kanwar et al. Chimeric aptamers in cancer cell-targeted drug delivery
CN101674810B (zh) 针对癌细胞和癌相关成纤维细胞的靶向剂
JP5398982B2 (ja) Ｒｎａリガンドを含むナノ粒子
CN104918639B (zh) 用于将治疗剂递送到活细胞和细胞核中的系统
Yang et al. Aptamers: an emerging navigation tool of therapeutic agents for targeted cancer therapy
Cibiel et al. In vivo uses of aptamers selected against cell surface biomarkers for therapy and molecular imaging
JP2016503394A (ja) 細胞型へのオリゴヌクレオチド分子の選択的送達のための組成物および方法
Malle et al. Programmable RNA loading of extracellular vesicles with toehold-release purification
US20240026357A1 (en) Modified mir-135, conjugated form thereof, and uses of same
Zhang et al. Dual radiosensitization and anti-STAT3 anti-proliferative strategy based on delivery of gold nanoparticle-oligonucleotide nanoconstructs to head and neck cancer cells
WO2015184224A1 (en) Aptamer targeting mage-a3 peptide and uses thereof
Huang et al. Acidic microenvironment triggered in situ assembly of activatable three-arm aptamer nanoclaw for contrast-enhanced imaging and tumor growth inhibition in vivo
CN101180400A (zh) 含有rna配体的纳米颗粒
US20240376472A1 (en) Conditional Double Stranded Antisense Oligonucleotides
WO2016094457A1 (en) Methods for treating basal-like and claudin-low breast cancer and combination therapies thereof
CN117440816A (zh) 修饰的mir-135、其缀合形式及其用途
Rychahou et al. Methods and assays for specific targeting and delivery of RNA nanoparticles to cancer metastases
Keyvani et al. Insight into RNA-based Therapies for Ovarian Cancer
WO2020218494A1 (ja) ｍｉＲ３０２核酸改変体
CN118497196B (zh) 用于递送siRNA的框架核酸机器及其制备方法与应用
Xiao et al. Application of Drug Liposomes in Gene Transfection
WO2024196422A1 (en) Dna nanodevices for specific and efficient delivery of functional payloads to the cytoplasm and methods of their use
WO2025231424A1 (en) Procapped mrna for targeted cell translation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160310

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170627